In the last trading session, 2.65 million shares of the Allogene Therapeutics Inc (NASDAQ:ALLO) were traded, and its beta was 0.84. Most recently the company’s share price was $2.19, and it changed around $0.05 or 2.34% from the last close, which brings the market valuation of the company to $469.91M. ALLO currently trades at a discount to its 52-week high of $5.78, offering almost -163.93% off that amount. The share price’s 52-week low was $1.99, which indicates that the current value has risen by an impressive 9.13% since then. We note from Allogene Therapeutics Inc’s average daily trading volume that its 10-day average is 2.5 million shares, with the 3-month average coming to 2.22 million.
Allogene Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.53. If we narrow it down even further, the data shows that 0 out of 18 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 5 recommended ALLO as a Hold, whereas 9 deemed it a Buy, and 0 rated it as Underweight. Allogene Therapeutics Inc is expected to report earnings per share of -0.32 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Instantly ALLO has showed a green trend with a performance of 2.34% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.59 on recent trading dayincreased the stock’s daily price by 15.44%. The company’s shares are currently down -31.78% year-to-date, but still down -11.69% over the last five days. On the other hand, Allogene Therapeutics Inc (NASDAQ:ALLO) is -31.99% down in the 30-day period. We can see from the shorts that 35.05 million shares have been sold at a short interest cover period of 14.97 day(s).
The consensus price target as assigned by Wall Street analysts is $33.5, which translates to bulls needing to increase their stock price by 93.46% from its current value. Analyst projections state that ALLO is forecast to be at a low of $7 and a high of $55.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
Allogene Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -5.60 percent over the past six months and at a 32.84% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be -71.12%, down from the previous year.
Consensus estimates provided by 17 financial analysts predict the company will bring in an average of 10.47k in revenue for the current quarter. 12 analysts expect Allogene Therapeutics Inc to make 4.17k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 21k and 22k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -50.14%. Forecasts for the next quarter put sales growth at -81.05%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.18%. Allogene Therapeutics Inc earnings are expected to increase by 36.47% in 2024, but the outlook is positive 1.00% per year for the next five years.
ALLO Dividends
Allogene Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 17.43% of Allogene Therapeutics Inc shares, and 80.22% of them are in the hands of institutional investors. The stock currently has a share float of 97.16%. Allogene Therapeutics Inc stock is held by 227.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 18.4816% of the shares, which is about 31.26 million shares worth $72.83 million.
TPG GP A, LLC, with 11.0663% or 18.72 million shares worth $43.61 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
